The Criticals for AGN And a Good Very Late Evening to All,
It was great to see/hear the updates with AGN today. The following are some of the take aways /criticals that I found were pertinent for my needs, as follows:
- 129.9M shares o/s
- 66.9M warrants/options
- 196.8M fully diluted shares
All 5 USA institutions are expected to be signed up in next 2 - 3 weeks. Miami is already the first & is expected to have the first patient signed up this week.
- $ 7.5M Cash on Hand as of 07/01/2020
- Cost of Phase 2 trialing of $ 5 - 6M. So that important cost is fully covered with looking at their Cash on hand.
- 50 % risk of failure in Phase 2. Note: 30% of this failure is due to Safety. This Ifendropil has been proven to have very few significant potential adverse affects. So the possibility of success appears much better for patients, AGN and we shareholders.
- dependent upon proven data results of Phase 2 may lead to emergency approval by FDA to combat covid 19 and it's aftermath.
- the AGN trials for each patient is approx 2 weeks from beginning to end. I believe it is approx another 2 weeks to review/analyze the data.
-Upon results of the Phase 2 trial ( 150 patients in total across 4 countries ), IMO, a successful outcome will lead to a dramatic sp move upwards.
- Costs of Phase 3 to be determined but with a success in Phase 2 the much higher AGN sp levels will minimize the # of shares @ the next public offering to raise more $$$. Note: Phase 3 is bacically the same as Phase 2. The difference is a larger # of patients to confirm the efficacy of the drug.
Best wishes to All, good health,
Sincerely,
Topseeker